A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States
Associates in Womens Health, PA - North Review, Wichita, Kansas, United States
Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States
Hôpital TENON, Service d'Oncologie Médicale, Paris, France
Stanford University Medical Center, Stanford, California, United States
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
Community Regional Cancer Center, Indianapolis, Indiana, United States
US Oncology, Houston, Texas, United States
Siteman Cancer Center, St. Louis, Missouri, United States
Hannover Medical School, Hannover, Germany
Groupe D´Etudes des Lymphomes De l´Adulte (GELA), Paris, France
German Low Grade Study Group (Glsg), Munich, Germany
The Maria Sklodowska Memorial, Cancer Center - Inst. of Oncology, Warszawa, Poland
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.